Orchard Therapeutics banks on lentiviral gene therapy potential

Armed with $110 million raised in a series B financing at the end of 2017, UK biotech Orchard Therapeutics is accelerating its efforts to lentiviral gene therapeutics into patients. Speaking at the 2018 Biotech Showcase, President & CEO Mark Rothera revealed to Scrip how the company, under its own steam, will strive to get approval for its lead program in ADA-SCID—so-called bubble baby syndrome—while advancing three other disclosed programs into the clinic in 2019.